Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T18:22:24.423Z.
Calculation as of: 2026-10-06T18:22:24.423Z.
Quote observation: 2026-10-06T18:20:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7a3ccde1bd0df5c55ebc0148063105fff0bf751cb52a3071af3e3331f6001fbe
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$502.60M
EV/FCF Ratio
16.73x
TTM Avg
14.11x
3Y Avg
11.22x
5Y Avg
269.81x
Market Cap
$487.34M
EV/FCF Ratio
11.09x
TTM Avg
7.76x
3Y Avg
12.39x
5Y Avg
16.55x
Market Cap
$510.55M
EV/FCF Ratio
937.40x
TTM Avg
716.21x
3Y Avg
716.21x
5Y Avg
716.21x
Market Cap
$475.90M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oculis Holding AG (OCS) | $496.43M | N/A | N/A | N/A | N/A |
| Tactile Systems Technology, Inc. (TCMD)vs › | $502.60M | 16.73x | 14.11x | 11.22x | 269.81x |
| Puma Biotechnology, Inc. (PBYI)vs › | $487.34M | 11.09x | 7.76x | 12.39x | 16.55x |
| Evolus, Inc. (EOLS)vs › | $486.55M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $507.38M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $509.99M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $510.55M | 937.40x | 716.21x | 716.21x | 716.21x |
| Alpha Teknova, Inc. (TKNO)vs › | $478.24M | N/A | N/A | N/A | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $475.90M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $475.52M | N/A | 5.27x | 5.30x | 11.22x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
